AstraZeneca terminates deal with Biota after trial failure
This article was originally published in Scrip
Executive Summary
AstraZeneca is to terminate its antiviral licensing agreement with Biota after the Australian company's BTA9881 failed to meet safety requirements in a Phase Ia clinical trial for respiratory synctial virus (RSV).